IMGN News and Press, ImmunoGen Inc. From 11/15/22

Oncology-focused biotech ImmunoGen, Inc. ( NASDAQ: IMGN ) shed ~12% on Tuesday after the company said it would launch the newly approved ovarian cancer drug Elahere "in a matter of days" at a list price of $6,220 per vial. "Most patients receive 3 to 4 vials per cycle, w...

The US FDA has granted accelerated approval to ImmunoGen ( NASDAQ: IMGN ) for Elahere (mirvetuximab soravtansine) , an antibody-drug conjugate ("ADC") for platinum-resistant ovarian cancer. Shares are up 9% in after-hours trading. The approval is specifically f...

ELAHERE is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin ® Use VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the Companion Diagnostic to I...

ImmunoGen, Inc. (IMGN) Q3 2022 Earnings Conference Call November 04, 2022, 08:00 ET Company Participants Anabel Chan - Head, Investor Relations Mark Enyedy - President, CEO & Director Anna Berkenblit - SVP & Chief Medical Officer Susan Altschuller - S...

ImmunoGen press release ( NASDAQ: IMGN ): Q3 GAAP EPS of -$0.31 misses by $0.05 . Revenue of $15.4M (+67.2% Y/Y) beats by $3.26M . ImmunoGen had $309.5M in cash and cash equivalents as of September 30, 2022, compared with $478.8M as of December 31, 2021. Ca...

Launch Preparations Completed Ahead of November 28, 2022 PDUFA Date Presentations at ESMO, IGCS, and ESGO Highlight Mirvetuximab’s Potential to Become New Standard of Care and Combination Agent of Choice in FRα-Positive Ovarian Cancer Initial Data fro...

ImmunoGen ( NASDAQ: IMGN ) is scheduled to announce Q3 earnings results on Friday, November 4th, before market open. The consensus EPS Estimate is -$0.25 (-38.9% Y/Y) and the consensus Revenue Estimate is $12.14M (+31.8% Y/Y). Over the last 1 year, IMGN has beaten EP...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith, Senior Vice President and Chief Commercial Officer (CCO), will be departing the Company. Ms. Harrington-Smit...

Patients with Extended Treatment Benefit Showed an Objective Response Rate of 77.5% and a Median Duration of Response of 22.1 Months Overall Adverse Event Profile Observed Consistent with Known Safety Profile of Mirvetuximab with Minimal Cumulative Toxicities Study Out...

Summary ImmunoGen has a PDUFA on November 28. The NDA is based on data from the Soraya trial. The PFS data creates some doubt in investors. ImmunoGen ( IMGN ) has a tryst with the FDA on November 28, a priority review of its BLA for mirvetuximab soravtansine back...